References

Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma

10.1111/j.1365-2141.2007.06796.x · 2007 · External reference

Paediatric non-Hodgkin lymphoma in low and middle income countries

10.1111/bjh.14030 · 2016 · External reference

Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children

10.1056/nejmoa1915315 · 2020 · External reference

Effectiveness of rituximab plus chemotherapy in pediatric Burkitt lymphoma: a systematic review and meta-analysis

10.1200/jco.2025.43.16_suppl.e22006 · 2025 · External reference

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

2023 · External reference

Pembrolizumab (pembro) in children and young adults with low-risk classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo): early results from the phase 2 keynote-667 study

10.1182/blood-2023-186719 · 2023 · External reference

Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group

10.1097/hs9.0000000000000329 · 2020 · External reference

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group

10.1182/blood-2012-05-431460 · 2012 · External reference

Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study

10.1200/jco.2023.41.16_suppl.10027 · 2023 · External reference

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial

10.1016/s1470-2045(19)30671-0 · 2020 · External reference

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial

10.1016/s1470-2045(20)30023-1 · 2020 · External reference

Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?

10.21037/atm.2020.04.54 · 2020 · External reference

Immune checkpoint inhibitors therapy as the game-changing approach for pediatric lymphoma: a brief landscape

10.1016/j.critrevonc.2023.104225 · 2024 · External reference

Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease

10.3389/fimmu.2024.1451977 · 2024 · External reference